Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy.

ABSTRACT:

Introduction

Diabetes is a common cause of end-stage kidney disease leading to dialysis or kidney transplantation. Estimated glomerular filtration rate (eGFR) measures kidney function, and differences in the rate (slope) of eGFR decline can be used to assess treatment effects on kidney function over time. In the CREDENCE trial, the sodium glucose co-transporter 2 inhibitor canagliflozin slowed the rate of eGFR decline by 60% compared to placebo in patients with diabetes and chronic kidney disease. This analysis utilized eGFR slopes from CREDENCE to estimate the difference in time to dialysis by treatment arm and estimated the economic value of that delay.

Methods

A linear decline in eGFR and maintenance of stable therapy were assumed for the canagliflozin and placebo arms in

SUBMITTER: Durkin M 

PROVIDER: S-EPMC7846621 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature